These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28117517)

  • 21. Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer.
    Mayer EL; Gropper AB; Harris L; Gold JM; Parker L; Kuter I; Come S; Najita JS; Guo H; Winer EP; Burstein HJ
    Clin Breast Cancer; 2015 Feb; 15(1):24-30. PubMed ID: 25205424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.
    Waks AG; Tolaney SM; Galar A; Arnaout A; Porter JB; Marty FM; Winer EP; Hammond SP; Baden LR
    Breast Cancer Res Treat; 2015 Nov; 154(2):359-67. PubMed ID: 26420402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant treatment in high-risk breast cancer.
    Jones A
    Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):156-8. PubMed ID: 8777488
    [No Abstract]   [Full Text] [Related]  

  • 24. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making?
    Antonio M; Saldaña J; Carmona-Bayonas A; Navarro V; Tebé C; Nadal M; Formiga F; Salazar R; Borràs JM
    Oncologist; 2017 Aug; 22(8):934-943. PubMed ID: 28487465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Should women with node-negative breast cancer receive adjuvant chemotherapy?--Insights from a decision analysis model.
    Hillner BE; Smith TJ
    Breast Cancer Res Treat; 1992; 23(1-2):17-27. PubMed ID: 1446048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.
    Torres S; Trudeau M; Eisen A; Earle CC; Chan KKW
    Breast Cancer Res Treat; 2015 Jul; 152(1):137-145. PubMed ID: 26026467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.
    Ragaz J; Olivotto IA; Spinelli JJ; Phillips N; Jackson SM; Wilson KS; Knowling MA; Coppin CM; Weir L; Gelmon K; Le N; Durand R; Coldman AJ; Manji M
    J Natl Cancer Inst; 2005 Jan; 97(2):116-26. PubMed ID: 15657341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long term side effects of adjuvant chemotherapy in patients with early breast cancer.
    Tao JJ; Visvanathan K; Wolff AC
    Breast; 2015 Nov; 24 Suppl 2(0 2):S149-53. PubMed ID: 26299406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy.
    Hurria A; Brogan K; Panageas KS; Pearce C; Norton L; Jakubowski A; Zauderer M; Howard J; Hudis C
    Breast Cancer Res Treat; 2005 Jul; 92(2):151-6. PubMed ID: 15986124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
    Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
    Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Offering a choice between two adjuvant chemotherapy regimens: a pilot study to develop a decision aid for women with breast cancer.
    Irwin E; Arnold A; Whelan TJ; Reyno LM; Cranton P
    Patient Educ Couns; 1999 Jul; 37(3):283-91. PubMed ID: 14528554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making.
    Chao C; Studts JL; Abell T; Hadley T; Roetzer L; Dineen S; Lorenz D; YoussefAgha A; McMasters KM
    J Clin Oncol; 2003 Dec; 21(23):4299-305. PubMed ID: 14581440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.
    Partin JF; Mamounas EP
    Ann Surg Oncol; 2011 Nov; 18(12):3399-406. PubMed ID: 21537874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer.
    Levine MN; Gafni A; Markham B; MacFarlane D
    Ann Intern Med; 1992 Jul; 117(1):53-8. PubMed ID: 1596048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A model of chemotherapy in node-negative breast cancer.
    Hillner BE; Smith TJ
    J Natl Cancer Inst Monogr; 1992; (11):143-9. PubMed ID: 1627420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).
    İçli F; Altundağ K; Akbulut H; Paydaş S; Başaran G; Saip P; Doğu GG; Eralp Y; Uslu R; Sevinç A; Onur H; Mandel NM; Sezgin C; Altınbaş M; Güler N; Işıkdoğan A; Gökmen E; Uygun K; Üstüner Z; Yaren A; Demirkan B; Coşkun U; Ata A; Özkan M; Arican A
    Breast Cancer; 2015 Sep; 22(5):480-5. PubMed ID: 24338610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.